Literature DB >> 18322369

Pathophysiology of neuronal energy crisis in Alzheimer's disease.

Jack C de la Torre1.   

Abstract

A large body of evidence indicates that sporadic Alzheimer's disease (AD) is a vascular disorder with neurodegenerative consequences and needs to be treated and managed as such. Epidemiologic studies of vascular risk factors, together with preclinical detection tools for AD are proof of concept that cerebral hypoperfusion is one of the earliest pathological signs in the development of cognitive failure. Vascular risk factors involving heart disease and stroke in the elderly individual who already possesses a dwindling cerebrovascular reserve due to advancing age contribute to further decline in cerebral blood flow (CBF) resulting in unrelenting brain hypoperfusion. Brain hypoperfusion, in turn, can reach a critically attained threshold of cerebral hypoperfusion (CATCH) giving rise to a neuronal energy crisis via reduced ATP synthesis. The ensuing metabolic energy crisis initially carves up ischemic-sensitive neurons in the hippocampus and posterior parietal cortex setting up cognitive meltdown and progressive neurodegenerative and atrophic changes in the brain. Neuronal energy compromise accelerates oxidative stress, excess production of reactive oxygen species, aberrant protein synthesis, ionic membrane pump dysfunction, signal transduction impairment, neurotransmitter failure, abnormal processing of amyloid precursor protein resulting in beta-amyloid deposition and axonal microtubule disruption from tau hyperphosphorylation. The high energy metabolic changes leading to oxidative stress and cellular hypometabolism precede clinical expression of AD. Regional CBF measurements using neuroimaging techniques can predict AD preclinically at the mild cognitive impairment stage or even before any clinical manifestation of dementia is expressed. Clinical diagnostic assessment of elderly persons who could develop or already present with memory complaints can prevent, reverse or slow down AD development. Although pathologic aging is the subject of thousands of studies, the question of why the elderly (and not younger people) succumb to AD has not been adequately addressed. The explanation(s) as to why vascular risk factors, for example, can trigger AD or vascular dementia usually in the elderly and not the young should provide vital clues in the search for a strategically effective dementia treatment. This review offers inductive hypothetical darts relative to that critical question. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 18322369     DOI: 10.1159/000113681

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  40 in total

1.  Alzheimer's dementia by circulation disorders: when trees hide the forest.

Authors:  Carlos G Dotti; Bart De Strooper
Journal:  Nat Cell Biol       Date:  2009-02       Impact factor: 28.824

2.  Treadmill Exercise Exerts Neuroprotection and Regulates Microglial Polarization and Oxidative Stress in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease.

Authors:  Yujiao Lu; Yan Dong; Donovan Tucker; Ruimin Wang; Mohammad Ejaz Ahmed; Darrell Brann; Quanguang Zhang
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 3.  Preventing Alzheimer's disease by means of natural selection.

Authors:  Lloyd A Demetrius; Jane A Driver
Journal:  J R Soc Interface       Date:  2015-01-06       Impact factor: 4.118

4.  The role of functional status on the relationship between blood pressure and cognitive decline: the Cardiovascular Health Study.

Authors:  Lindsay M Miller; Carmen A Peralta; Annette L Fitzpatrick; Chenkai Wu; Bruce M Psaty; Anne B Newman; Michelle C Odden
Journal:  J Hypertens       Date:  2019-09       Impact factor: 4.844

5.  Genetic variation of oxidative phosphorylation genes in stroke and Alzheimer's disease.

Authors:  Alessandro Biffi; Mert R Sabuncu; Rahul S Desikan; Nick Schmansky; David H Salat; Jonathan Rosand; Christopher D Anderson
Journal:  Neurobiol Aging       Date:  2014-02-05       Impact factor: 4.673

6.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

7.  Microvascular perfusion based on arterial spin labeled perfusion MRI as a measure of vascular risk in Alzheimer's disease.

Authors:  Quan Zhang; Randall B Stafford; Ze Wang; Steven E Arnold; David A Wolk; John A Detre
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 8.  The dementia of cardiac disease.

Authors:  Hurmina Muqtadar; Fernando D Testai; Philip B Gorelick
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

Review 9.  Mouse models to study the effect of cardiovascular risk factors on brain structure and cognition.

Authors:  Diewertje I Bink; Katja Ritz; Eleonora Aronica; Louise van der Weerd; Mat J A P Daemen
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-21       Impact factor: 6.200

10.  Estradiol Protects White Matter of Male C57BL6J Mice against Experimental Chronic Cerebral Hypoperfusion.

Authors:  Reymundo Dominguez; Madison Zitting; Qinghai Liu; Arati Patel; Robin Babadjouni; Drew M Hodis; Robert H Chow; William J Mack
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-03-27       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.